ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Resources and Suppliers
Online/telemedicine script for Natesto & Enclomiphene?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tareload" data-source="post: 224162"><p>[URL unfurl="true"]https://www.fda.gov/advisory-committees/advisory-committee-calendar/june-8-2022-meeting-pharmacy-compounding-advisory-committee-meeting-announcement-06082022?utm_medium=email&utm_source=govdelivery[/URL]</p><p></p><h2><strong>FDA announces Pharmacy Compounding Advisory Committee Meeting</strong></h2><p>The Food and Drug Administration will hold a <a href="https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMjA1MTkuNTgxNDk0NzEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L2Fkdmlzb3J5LWNvbW1pdHRlZXMvYWR2aXNvcnktY29tbWl0dGVlLWNhbGVuZGFyL2p1bmUtOC0yMDIyLW1lZXRpbmctcGhhcm1hY3ktY29tcG91bmRpbmctYWR2aXNvcnktY29tbWl0dGVlLW1lZXRpbmctYW5ub3VuY2VtZW50LTA2MDgyMDIyP3V0bV9tZWRpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.scoakK1dJ0u48pH1daRJ8M7FnZdNmDriRaX6yBWFaxc/s/1257248959/br/131568859963-l" target="_blank">Pharmacy Compounding Advisory Committee (PCAC) meeting</a> on June 8, 2022, to discuss four bulk drug substances nominated for inclusion on FDA’s list of bulk drug substances that can be used in compounding under section 503A of the Federal Food, Drug and Cosmetic Act (503A Bulks List) and a potential addition to the withdrawn or removed list.</p><p></p><p>The following four bulk drug substances are nominated for inclusion on the 503A Bulks List:</p><p></p><ul> <li data-xf-list-type="ul">ammonium tetrathiomolybdate,</li> <li data-xf-list-type="ul"><strong><strong>enclomiphene citrate,</strong></strong></li> <li data-xf-list-type="ul">ferric subsulfate, and</li> <li data-xf-list-type="ul">glutathione</li> </ul><p>The committee will also discuss revisions FDA is considering to the <a href="https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDIsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMjA1MTkuNTgxNDk0NzEiLCJ1cmwiOiJodHRwczovL2VjZnIuaW8vVGl0bGUtMjEvU2VjdGlvbi0yMTYuMjQ_dXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPWdvdmRlbGl2ZXJ5In0.O2U5Mddaf_BgZQ4IBWA0q8Q2g_OCd1B356wIDfrSn38/s/1257248959/br/131568859963-l" target="_blank">Withdrawn or Removed List </a>of drug products that may not be compounded under the exemptions provided by section 503A(a) or section 503B(a) of the Federal Food, Drug, and Cosmetic Act. FDA now is considering whether to amend the rule to add one more entry to the list: lorcaserin hydrochloride and all drug products containing lorcaserin hydrochloride.</p><p></p><p>The meeting will take place virtually only on:</p><p></p><p><strong>Date: June 8, 2022</strong></p><p><strong></strong></p><p><strong>Time: 9:30 AM - 5:15 PM ET</strong></p><p></p><p></p><p>[ATTACH=full]21870[/ATTACH]</p><p></p><p></p><p>Two days prior to the meeting, FDA will provide the live webcast link on the <a href="https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDMsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMjA1MTkuNTgxNDk0NzEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L2Fkdmlzb3J5LWNvbW1pdHRlZXMvcGhhcm1hY3ktY29tcG91bmRpbmctYWR2aXNvcnktY29tbWl0dGVlLzIwMjItbWVldGluZy1tYXRlcmlhbHMtcGhhcm1hY3ktY29tcG91bmRpbmctYWR2aXNvcnktY29tbWl0dGVlP3V0bV9tZWRpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.GSdtbnUcTu9KuQ0CcpywDoWj2QGSyqYx2Wpq0aGUP3U/s/1257248959/br/131568859963-l" target="_blank">2022 Meeting Materials, Pharmacy Compounding Advisory Committee</a> webpage.</p><p></p><p>Comments can be submitted electronically to the <a href="https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDQsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMjA1MTkuNTgxNDk0NzEiLCJ1cmwiOiJodHRwczovL3d3dy5yZWd1bGF0aW9ucy5nb3YvZG9jdW1lbnQvRkRBLTIwMjEtTi0wMzU3LTI1ODY_dXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPWdvdmRlbGl2ZXJ5In0.WQTclHYJFjph5fnk-d3t2DSVlQt1RyMvQfYuWekXURg/s/1257248959/br/131568859963-l" target="_blank">docket</a> for this meeting or through mail/hand/delivery courier. Comments received on or before May 24, 2022, will be provided to the committee. Comments received after that date but by June 7, 2022, will be taken into consideration by FDA. If the meeting is cancelled, FDA will continue to evaluate any relevant applications or information, and consider any comments submitted to the docket, as appropriate.</p></blockquote><p></p>
[QUOTE="tareload, post: 224162"] [URL unfurl="true"]https://www.fda.gov/advisory-committees/advisory-committee-calendar/june-8-2022-meeting-pharmacy-compounding-advisory-committee-meeting-announcement-06082022?utm_medium=email&utm_source=govdelivery[/URL] [HEADING=1][B]FDA announces Pharmacy Compounding Advisory Committee Meeting[/B][/HEADING] The Food and Drug Administration will hold a [URL='https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMjA1MTkuNTgxNDk0NzEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L2Fkdmlzb3J5LWNvbW1pdHRlZXMvYWR2aXNvcnktY29tbWl0dGVlLWNhbGVuZGFyL2p1bmUtOC0yMDIyLW1lZXRpbmctcGhhcm1hY3ktY29tcG91bmRpbmctYWR2aXNvcnktY29tbWl0dGVlLW1lZXRpbmctYW5ub3VuY2VtZW50LTA2MDgyMDIyP3V0bV9tZWRpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.scoakK1dJ0u48pH1daRJ8M7FnZdNmDriRaX6yBWFaxc/s/1257248959/br/131568859963-l']Pharmacy Compounding Advisory Committee (PCAC) meeting[/URL] on June 8, 2022, to discuss four bulk drug substances nominated for inclusion on FDA’s list of bulk drug substances that can be used in compounding under section 503A of the Federal Food, Drug and Cosmetic Act (503A Bulks List) and a potential addition to the withdrawn or removed list. The following four bulk drug substances are nominated for inclusion on the 503A Bulks List: [LIST] [*]ammonium tetrathiomolybdate, [*][B][B]enclomiphene citrate,[/B][/B] [*]ferric subsulfate, and [*]glutathione [/LIST] The committee will also discuss revisions FDA is considering to the [URL='https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDIsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMjA1MTkuNTgxNDk0NzEiLCJ1cmwiOiJodHRwczovL2VjZnIuaW8vVGl0bGUtMjEvU2VjdGlvbi0yMTYuMjQ_dXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPWdvdmRlbGl2ZXJ5In0.O2U5Mddaf_BgZQ4IBWA0q8Q2g_OCd1B356wIDfrSn38/s/1257248959/br/131568859963-l']Withdrawn or Removed List [/URL]of drug products that may not be compounded under the exemptions provided by section 503A(a) or section 503B(a) of the Federal Food, Drug, and Cosmetic Act. FDA now is considering whether to amend the rule to add one more entry to the list: lorcaserin hydrochloride and all drug products containing lorcaserin hydrochloride. The meeting will take place virtually only on: [B]Date: June 8, 2022 Time: 9:30 AM - 5:15 PM ET[/B] [ATTACH type="full"]21870[/ATTACH] Two days prior to the meeting, FDA will provide the live webcast link on the [URL='https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDMsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMjA1MTkuNTgxNDk0NzEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L2Fkdmlzb3J5LWNvbW1pdHRlZXMvcGhhcm1hY3ktY29tcG91bmRpbmctYWR2aXNvcnktY29tbWl0dGVlLzIwMjItbWVldGluZy1tYXRlcmlhbHMtcGhhcm1hY3ktY29tcG91bmRpbmctYWR2aXNvcnktY29tbWl0dGVlP3V0bV9tZWRpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.GSdtbnUcTu9KuQ0CcpywDoWj2QGSyqYx2Wpq0aGUP3U/s/1257248959/br/131568859963-l']2022 Meeting Materials, Pharmacy Compounding Advisory Committee[/URL] webpage. Comments can be submitted electronically to the [URL='https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDQsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMjA1MTkuNTgxNDk0NzEiLCJ1cmwiOiJodHRwczovL3d3dy5yZWd1bGF0aW9ucy5nb3YvZG9jdW1lbnQvRkRBLTIwMjEtTi0wMzU3LTI1ODY_dXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPWdvdmRlbGl2ZXJ5In0.WQTclHYJFjph5fnk-d3t2DSVlQt1RyMvQfYuWekXURg/s/1257248959/br/131568859963-l']docket[/URL] for this meeting or through mail/hand/delivery courier. Comments received on or before May 24, 2022, will be provided to the committee. Comments received after that date but by June 7, 2022, will be taken into consideration by FDA. If the meeting is cancelled, FDA will continue to evaluate any relevant applications or information, and consider any comments submitted to the docket, as appropriate. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Resources and Suppliers
Online/telemedicine script for Natesto & Enclomiphene?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top